Advertisement
Advertisement
Trending on Urology Times
1
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Dabogratinib shows early activity in FGFR3-altered LG-IR-NMIBC
4
The critical role of advocacy in urologic oncology
5
